Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Mar 02, 2022 1:52pm
106 Views
Post# 34475844

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructive

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructiveEngage them with what???? Buy our stock, but all we have to sell for now is hope that it will work some day? Time for hope is well passed for Thera. They need strong results to be able to convince new investors and they cannot disclose important material infos to selected investors. That being said, they can do it under confidentiality agreements with potential partners. But if what they see now shows a proof of concept, they are better to wait before signing a partnership. They have enough money to run the phase Ib. At this point info release is highly strategic from a financing point of view. If they have something, a likely proof of concept, they need to play their cards properly. But with covid, now with the war in Ukraine, it's a moving landscape. Not the easiest situation.

Scioto1 wrote:
If you read through my thread you'll see that I acknowledge that our clinical work and project development is critical. But I think it's Also an important responsibility of management to engage shareholders, engage potential institutional investors, engage analysts, and advance a public information campaign plan all with an eye towards shareholder value. I'm not talking about creating it out of thin air. It needs to be an important priority just like the research and development.


<< Previous
Bullboard Posts
Next >>